Russian Registry of Patients With nAMD

Russian Registry of Patients With Neovascular Age-Related Macular Degeneration (nAMD)

ClinicalTrials.gov Identifier: NCT04935411

Novartis Reference Number: CRTH258ARU01

Last Update: Jul 08, 2021

See if you pre-qualify

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. 

Study Description

A three-year, non-randomized, observational, multicenter prospective nAMD study - patient registry.

Condition 
Neovascular Age-Related Macular Degeneration
Phase 
Not Given
Overall status 
Recruiting
Start date 
Dec 20, 2020
Completion date 
Jun 30, 2023
Gender 
All
Age(s)
18 Years and older (Adult, Older Adult)

Interventions

Other
nAMD
patients diagnosed with Neovascular Age-Related Macular Degeneration

Eligibility Criteria

Inclusion Criteria:

Age > to 18 years
Male or female patients diagnosed with nAMD (with or without previous treatment for nAMD including but not limited to PDT, laser coagulation, vitamins, retinolamine, emoxipine, anti-VEGF therapy or any surgery for nAMD).
Willing and able to provide informed written consent personally or by legal proxy

Exclusion Criteria:

The patient does not meet the inclusion criteria;
The patient is simultaneously participating in a different nAMD therapy study.

Study Locations

Russian Federation
Novartis Investigative Site
Recruiting
Novosibirsk, 630087
-
Russian Federation

Contacts

Name: 
Novartis Pharmaceuticals
Phone: 

Have a question?

Call 1-888-669-6682 or email [email protected]